insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

[Tumor flare reaction during epcoritamab treatment in refractory diffuse large B-cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology 2026 Vol.67(2) p. 109-113

Fujiwara Y, Tsuchida H, Kawatsuki A, Kobayashi H, Yamasaki T, Asano T, Hiramatsu Y

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

An 87-year-old man was diagnosed with diffuse large B-cell lymphoma in 2020.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Fujiwara Y, Tsuchida H, et al. (2026). [Tumor flare reaction during epcoritamab treatment in refractory diffuse large B-cell lymphoma].. [Rinsho ketsueki] The Japanese journal of clinical hematology, 67(2), 109-113. https://doi.org/10.11406/rinketsu.67.109
MLA Fujiwara Y, et al.. "[Tumor flare reaction during epcoritamab treatment in refractory diffuse large B-cell lymphoma].." [Rinsho ketsueki] The Japanese journal of clinical hematology, vol. 67, no. 2, 2026, pp. 109-113.
PMID 41780953
DOI 10.11406/rinketsu.67.109

Abstract

An 87-year-old man was diagnosed with diffuse large B-cell lymphoma in 2020. The disease relapsed repeatedly and remained poorly controlled despite multiple salvage chemotherapy regimens. In February 2024, inguinal lymphadenopathy reappeared and epcoritamab was administered as the sixth line of chemotherapy. Tumor area assessment showed transient increases on days 4, 12, and 17. Macroscopic redness and elevation were also observed. This was considered a tumor flare reaction because it disappeared transiently. We report this case as an example of successful serial imaging of lesions from the start of epcoritamab therapy to visually confirm changes that may constitute a tumor flare reaction.

MeSH Terms

Aged, 80 and over; Humans; Male; Lymphoma, Large B-Cell, Diffuse; Antibodies, Bispecific; Antibodies, Monoclonal

같은 제1저자의 인용 많은 논문 (5)